AGENUS INC

AGENSEC EDGAR

Biological Products, (No Diagnostic Substances)(DE)CIK: 1098972

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue from Contract with Customer, Excluding Assessed Tax	$98.0M	$295.7M	$88.2M	$150.0M	$36.8M
Cost of Revenue	$10.6M	$3.5M	$2.3M	$2.3M	$2.3M
Research and Development Expense	$186.7M	$178.6M	$142.6M	$168.3M	$124.6M
Operating Income (Loss)	-$179.4M	$25.7M	-$117.2M	-$70.1M	-$123.8M
Interest Expense	—	—	—	—	—
Nonoperating Income (Expense)	$12.6M	$5.1M	-$1.9M	$28.0K	-$2.2M
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$313.9M	$413.6M	$466.0M	$214.5M	$155.3M
Assets, Current	$112.4M	$213.1M	$332.0M	$113.8M	$86.5M
Cash and Cash Equivalents, at Carrying Value	$178.7M	$291.9M	$99.9M	$61.8M	$53.1M
Accounts Receivable, after Allowance for Credit Loss, Current	$25.8M	$2.7M	$1.5M	$1.2M	$16.3M
Inventory, Net	—	—	—	—	—
Liabilities, Current	$255.9M	$189.0M	$156.9M	$129.9M	$122.2M
Long-term Debt	$33.2M	—	—	—	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$175.4M	$10.1M	-$139.1M	-$18.7M	-$131.1M
Net Cash Provided by (Used in) Investing Activities	-$33.6M	-$43.1M	-$4.4M	-$4.7M	-$3.6M
Net Cash Provided by (Used in) Financing Activities	$95.8M	$225.3M	$183.9M	$31.3M	$128.3M
Payments to Acquire Property, Plant, and Equipment	$53.1M	$33.8M	$3.5M	$4.7M	$3.6M
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)